Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−7.95 USD
−58.98 M USD
0.00 USD
15.23 M
About Outlook Therapeutics, Inc.
Sector
CEO
C. Russell Trenary
Headquarters
Iselin
Website
Founded
2010
FIGI
BBG00469JRJ5
Outlook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of ONS-5010/LYTENAVA. Its pipeline includes unmet patient needs, repackaged IV bevacizumab, and anti-VEGF. The company was founded by Pankaj Mohan on January 5, 2010 and is headquartered in Iselin, NJ.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of OTLK is 5.13 USD — it has increased by 0.96% in the past 24 hours. Watch Outlook Therapeutics, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Outlook Therapeutics, Inc. stocks are traded under the ticker OTLK.
OTLK stock has fallen by −15.92% compared to the previous week, the month change is a −2.58% fall, over the last year Outlook Therapeutics, Inc. has showed a −42.14% decrease.
We've gathered analysts' opinions on Outlook Therapeutics, Inc. future price: according to them, OTLK price has a max estimate of 53.00 USD and a min estimate of 30.00 USD. Watch OTLK chart and read a more detailed Outlook Therapeutics, Inc. stock forecast: see what analysts think of Outlook Therapeutics, Inc. and suggest that you do with its stocks.
OTLK reached its all-time high on Sep 1, 2016 with the price of 878.40 USD, and its all-time low was 4.00 USD and was reached on Sep 8, 2023. View more price dynamics on OTLK chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
OTLK stock is 4.55% volatile and has beta coefficient of 0.42. Track Outlook Therapeutics, Inc. stock price on the chart and check out the list of the most volatile stocks — is Outlook Therapeutics, Inc. there?
Today Outlook Therapeutics, Inc. has the market capitalization of 124.90 M, it has decreased by −4.17% over the last week.
Yes, you can track Outlook Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
Outlook Therapeutics, Inc. is going to release the next earnings report on Dec 19, 2024. Keep track of upcoming events with our Earnings Calendar.
OTLK earnings for the last quarter are −0.83 USD per share, whereas the estimation was −1.03 USD resulting in a 19.64% surprise. The estimated earnings for the next quarter are −0.80 USD per share. See more details about Outlook Therapeutics, Inc. earnings.
Outlook Therapeutics, Inc. revenue for the last quarter amounts to 0.00 USD, matching the estimated figure, and no changes in revenue are expected for the next quarter.
OTLK net income for the last quarter is 44.41 M USD, while the quarter before that showed −114.29 M USD of net income which accounts for 138.86% change. Track more Outlook Therapeutics, Inc. financial stats to get the full picture.
No, OTLK doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 21, 2024, the company has 24.00 employees. See our rating of the largest employees — is Outlook Therapeutics, Inc. on this list?
Like other stocks, OTLK shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Outlook Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Outlook Therapeutics, Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Outlook Therapeutics, Inc. stock shows the sell signal. See more of Outlook Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.